Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial
2021 ◽
Vol 8
(12)
◽
pp. e879-e890
◽
2019 ◽
Vol 6
(9)
◽
pp. e470-e479
◽
2007 ◽
Vol 136
(3)
◽
pp. 379-392
◽
2016 ◽
Vol 176
(4)
◽
pp. 573-582
◽